Candel Therapeutics（纳斯达克代码：CADL）近日宣布与生物医药投资机构RTW达成一项规模达1亿美元的特许权融资协议。该资金将专项用于支持其核心候选药物Aglatigmatene Besadenovec（研发代号CAN-2409）在局限性前列腺癌领域的潜在商业化推进。此次合作通过未来药物销售的特许权收益作为融资对价，在降低股权稀释风险的同时，为CAN-2409的临床开发及市场准入提供关键资金支持。
CAN-2409作为一种基于腺病毒载体的免疫激活疗法，已在前列腺癌的临床研究中展现出激活患者自身免疫系统对抗肿瘤的潜力。此次融资协议的落地，标志着该疗法向商业化阶段迈出关键一步，也为晚期前列腺癌患者提供了新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.